You are here
mCRPC: Alternative starting points
Professor Noel W Clarke, Salford Royal Hospital and The Christie, Manchester, continues with his case report of a 58 year old man with asymptomatic adenocarcinoma of the prostate (cT3 Gleason) treated initially with androgen ablation monotherapy followed by 6 cycles of androgen deprivation therapy (ADT) and docetaxel (with G-CSF). The prostate-specific antigen nadir response was 1.3 ng/ml. The audience is asked to vote for treatment with ADT alone, ADT plus bicalutamide, novel androgen targeting agents or rechallenge with docetaxel.